ContractPlacement Agency Agreement • May 23rd, 2024 • Volato Group, Inc. • Air transportation, nonscheduled • New York
Contract Type FiledMay 23rd, 2024 Company Industry Jurisdiction
Imunon, Inc. Attention: Dr. Corinne Le GoffPlacement Agency Agreement • January 18th, 2024 • Imunon, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 18th, 2024 Company Industry Jurisdiction
Re: Placement Agency AgreementPlacement Agency Agreement • December 6th, 2023 • iBio, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 6th, 2023 Company Industry JurisdictionSubject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (“A.G.P.”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) as co-placement agent (A.G.P. and Brookline are also referred to herein, collectively, as the “Placement Agents”), and iBio, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) Series C and Series D warrants to purchase Common Stock (collectively, the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warr
Re: Placement Agency AgreementPlacement Agency Agreement • November 30th, 2023 • iBio, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 30th, 2023 Company Industry JurisdictionSubject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (“A.G.P.”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) as co-placement agent (A.G.P. and Brookline are also referred to herein, collectively, as the “Placement Agents”), and iBio, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) Series C and Series D warrants to purchase Common Stock (collectively, the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warr
Re: Placement Agency AgreementPlacement Agency Agreement • October 27th, 2023 • iBio, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 27th, 2023 Company Industry JurisdictionSubject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (“A.G.P.”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) as co-placement agent (A.G.P. and Brookline are also referred to herein, collectively, as the “Placement Agents”), and iBio, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually sold by the Placement
Tonix Pharmaceuticals Holding Corp. 8-KPlacement Agency Agreement • September 29th, 2023 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 29th, 2023 Company Industry JurisdictionSubject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (“A.G.P.”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) as co-placement agent (A.G.P. and Brookline are also referred to herein, collectively, as the “Placement Agents”), and Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) Series A warrants and Series B warrants to purchase Common Stock (collectively, the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warra
Tonix Pharmaceuticals Holding Corp. 8-KPlacement Agency Agreement • July 28th, 2023 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Contract Type FiledJuly 28th, 2023 Company Industry JurisdictionSubject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (“A.G.P.”), as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) as co-placement agent (A.G.P. and Brookline are also referred to herein, collectively, as the “Placement Agents”), and Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually